Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.
The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia.
Egerer
G
G
Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115 Heidelberg, Germany.
Sauerland
K
K
Ho
A D
AD
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001772:Blood Cell Count; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010198:Pancytopenia / Q000139:chemically induced*; D011241:Prednisone / Q000008:administration & dosage; D012010:Red-Cell Aplasia, Pure / Q000097:blood / Q000139:chemically induced*; D000069283:Rituximab; D016896:Treatment Outcome; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone